425: Arcadia Biosciences Merger with Roosevelt Resources Ends

Arcadia Biosciences announced the termination of its proposed business combination with Roosevelt Resources, prompting a renewed search for strategic alternatives.

Summary

• Arcadia Biosciences, Inc. (RKDA) received notice on December 24, 2025, from Roosevelt Resources, LP, terminating their Securities Exchange Agreement.
• The agreement, originally dated December 4, 2024, provided for an all-stock business combination between the two companies.
• The termination occurred because the closing of the Exchange had not happened by the amended termination date of August 15, 2025.
• Arcadia does not believe that any break-up fee or similar payment will be payable by either party in connection with the termination.
• The company will now resume the process of evaluating strategic alternatives to create value for shareholders.

Sentiment

Score: 2

Explanation: The termination of a major strategic transaction, coupled with an explicit statement about the immediate need for additional funding and the severe risks associated with not securing it (including potential liquidation or bankruptcy), indicates a highly negative outlook for the company's near-term future. While management highlights some existing assets and operational improvements, the core news is a significant setback and raises going concern issues.

Positives

• Streamlined operations and significantly reduced operating expenses over the last two-and-a-half years.
• Grew the Zola coconut water brand while avoiding the use of long-term debt.
• Owns approximately 2.7 million shares of Above Food Ingredients Inc. common stock.
• Believes it is entitled to additional consideration and compensation relating to the May 2024 sale of GoodWheat™.
• Possesses a Nasdaq public listing and the Zola business, which management believes makes it an attractive candidate for a merger or other strategic transaction.

Negatives

• Termination of the proposed business combination with Roosevelt Resources, LP, a key strategic initiative.
• Requires additional funding in the near future to continue operations and planned activities.
• There are no assurances that required funding will be available at all, in sufficient amounts, or on reasonable terms.
• Any sale of additional equity securities to raise funds could result in material dilution to company stockholders.
• Failure to secure adequate additional funding could lead to reduced or suspended activities, asset liquidation, or initiation of dissolution and liquidation or bankruptcy proceedings, potentially rendering common stock with little or no value.

Risks

• Uncertainty regarding the company's ability to secure additional funding to continue its operations and planned activities.
• Risk that required funding may not be available at all, in sufficient amounts, or on reasonable terms.
• Potential for material dilution to stockholders if additional equity securities are sold to raise capital.
• Risk of being required to reduce or suspend activities, liquidate assets, or initiate dissolution/liquidation/bankruptcy proceedings if adequate funding is not secured.
• In the event of such proceedings, Arcadia's creditors would have first claim on assets, and common stock would likely have little or no value.
• Uncertainty regarding the company's ability to pursue and enter into alternative strategic transactions.
• Uncertainty concerning the company's entitlement to additional shares of Above Food Ingredients Inc. common stock and principal and interest payments owed by Above Foods Corp.

Future Outlook

Arcadia Biosciences will resume evaluating strategic alternatives to create value for shareholders, leveraging its streamlined operations, reduced expenses, Zola brand growth, existing assets (including 2.7 million ABVE shares and potential GoodWheat™ compensation), and Nasdaq listing. However, the company explicitly states it requires additional funding in the near future to continue operations, with no assurance of availability or reasonable terms, posing a significant risk to its continued viability.

Management Comments

• "In light of these circumstances, Arcadia will resume the process of evaluating strategic alternatives in order to create value for our shareholders."
• "Over the last two-and-a-half years, we have streamlined our operations, significantly reduced our operating expenses and grown the Zola coconut water brand while avoiding the use of long-term debt."
• "We continue to own approximately 2.7 million shares of Above Food Ingredients Inc. common stock and believe we are entitled to additional consideration and compensation relating to our May 2024 sale of GoodWheat™."
• "We believe these assets, along with our Nasdaq public listing and our Zola business, should make Arcadia an attractive candidate for a merger or other strategic transaction."

Industry Context

The termination of this proposed business combination leaves Arcadia Biosciences, a company focused on innovative wellness products, in a position where it must actively seek new strategic partners or transactions. In an industry that often sees consolidation and strategic alliances, Arcadia's ability to attract a suitable partner will be crucial, especially given its stated need for additional funding. The company's existing assets, like the Zola brand and ABVE shares, position it as a potential target, but the immediate funding requirement adds pressure in a competitive market for strategic transactions.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders face significant uncertainty regarding the company's future strategic direction and financial viability. There is a potential for material dilution if equity is raised, or a substantial loss of investment if the company faces liquidation or bankruptcy.
• Employees may be impacted by potential reductions in activities or suspension of operations if adequate funding is not secured.
• Creditors would have first claim on the company's assets in the event of liquidation or bankruptcy proceedings.

Next Steps

• Resume the process of evaluating strategic alternatives to create value for shareholders.
• Seek additional funding through equity or debt financings to support ongoing operations.

Key Dates

Recommendation

The termination of a significant business combination, especially after an extension, signals a failure in a key strategic initiative. More critically, the explicit disclosure that Arcadia Biosciences 'will require additional funding in the near future' and the severe risks associated with not securing it (including potential liquidation or bankruptcy where common stock would likely have little or no value) point to a highly precarious financial position. While management highlights some positive operational aspects and existing assets, the immediate and critical funding need, coupled with the failure of the merger, creates substantial downside risk for shareholders. An investor should consider exiting their position to avoid potential significant losses.

Keywords

Arcadia Biosciences, RKDA, Roosevelt Resources, Merger Termination, Business Combination, Strategic Alternatives, SEC Filing, Form 8-K, Wellness Products, Zola, Above Food Ingredients, GoodWheat, Nasdaq